title: [Susceptibility to antibiotics of Escherichia coli isolated from community-acquired urinary tract infections].
abstract: OBJECTIVE
  The authors had for aim to determine the distribution of bacterial isolates and the antibiotic susceptibility patterns of Escherichia coli from community-acquired urinary tract infections in an area covering 57,000 people (Elbeuf, Normandie, France).
  
  
  METHODS
  From November 2007 to October 2008, three private French laboratories consecutively collected 2344 bacteria including 1636 E. coli from outpatients. The antibiotic susceptibility of E. coli was determined using an automatized method (Vitek 2 Biomerieux).
  
  
  RESULTS
  The global susceptibility of E. coli was: ampicillin: 57%; amoxicillin+clavulanic acid: 73%; cefixim: 96%; ceftriaxone: 98%; gentamycin: 96%; nalidixic acid: 82%; ciprofloxacin: 89%; fosfomycin: 98%; nitrofurantoin: 96% and cotrimoxazole: 81%. The susceptibility of E. coli to ciprofloxacin was higher in 15- to 65-year-old female patients (94%) than for older female (85%) or male patients (80%).
  
  
  CONCLUSIONS
  In the Elbeuf area, third generation cephalosporins, aminoglycosides, nitrofurantoin, and fosfomycin were the most effective on E. coli isolated from community-acquired urinary tract infections. Fluoroquinolones were more active in 15- to 65-year-old female patients than in male patients and in female patients over 65 years of age. The rates of acquired resistance were related to the level of antibiotic prescription in the various populations.
authors.affiliation: Label Bio, 36, rue du Neubourg 76500 Elbeuf, France. roland.fabre0781@orange.fr
authors.forename: R
authors.initials: R
authors.lastname: Fabre
authors.forename: A
authors.initials: A
authors.lastname: Mérens
authors.forename: F
authors.initials: F
authors.lastname: Lefebvre
authors.forename: G
authors.initials: G
authors.lastname: Epifanoff
authors.forename: F
authors.initials: F
authors.lastname: Cerutti
authors.forename: H
authors.initials: H
authors.lastname: Pupin
authors.forename: D
authors.initials: D
authors.lastname: Tardif
authors.forename: J-D
authors.initials: JD
authors.lastname: Cavallo
authors.forename: I
authors.initials: I
authors.lastname: Ternois
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology*; D055815:Young Adult